Enable Innovation. Unlock Potential.
Unlock actionable insights from all your R&D data to determine the right target, right tissue, right patient, right safety, and right commercial potential.
From Biomarker Discovery to IVD.
Link biomarker, omics, and imaging data to clinical outcomes to support mechanism-of-action or responder enrichment strategies — enabling more targeted and efficient trials.
Prioritize biomarker signatures taking the final IVD platform characteristics into account, decreasing failures
Reach the Right Patients.
Improve Trial Success.
Real-time access to curated, analysis-ready data to interpret pre-clinical and exploratory clinical trial data – defining the indication and patient population with the highest benefit from the new treatment.
Unlock New Indications.
Maximize Value.
Connect legacy clinical trial data, real-world evidence, and mechanistic studies to identify and validate new indications for existing compounds - maximizing clinical impact/efficacy and financial return.
Working closely with Genedata, we have generated a digital biomarker research platform that will enable Merck scientists to better utilize clinical and translational data to generate innovative ideas for new biomarkers and drug targets.
We are pleased to have found a reliable partner who provided us with expert knowledge in big multi-omics data analysis to accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions.
We chose Genedata Profiler because it is the end-to-end enterprise software able to harmonize our dispersed data analysis pipelines, enhancing our capacity to analyze large amounts of high-dimensional ‘omics data emerging from our rapidly growing number of translational and clinical research projects.
As we expect our clinical and pre-clinical programs and pipeline to continue to grow, we look forward to utilizing Genedata Profiler and Genedata Managed IT Services to assist us in our mission to develop safe, targeted, effective therapeutics for cancer patients.
